PreviPharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PreviPharma Consulting GmbH, founded in 2018 and headquartered in Hamburg, Germany, is a specialized service provider and research partner to the global plasma fractionation industry. The company offers comprehensive R&D support across the entire value chain, including medical strategy, process development, preclinical and clinical studies, analytical methods, and contract manufacturing. With a team of approximately 70, proprietary preclinical assets, and facilities in Mannheim and Hyderabad, it positions itself as an accelerator for plasma protein innovations.

OncologyInfectious Disease

Technology Platform

Integrated service platform for plasma fractionation R&D, combining proprietary knowledge of plasma proteins, process development expertise, GLP/GMP-compliant manufacturing, and a network of scientific partners.

Opportunities

The growing, multi-billion dollar plasma-derived therapeutics market relies on complex R&D and manufacturing, creating strong demand for specialized outsourcing partners.

PreviPharma's end-to-end services and proprietary asset base position it to capture this demand and form deeper, strategic co-development partnerships with fractionators.

Risk Factors

Revenue is entirely dependent on the outsourcing budgets of a concentrated client base in the plasma industry, creating client concentration risk.

As a service provider, its growth and valuation may be limited compared to asset-owning biotechs, and it faces operational risks in maintaining expensive, state-of-the-art facilities and talent.

Competitive Landscape

PreviPharma competes with other contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) that offer plasma or biologics services, such as Lonza, Charles River Laboratories, and Samsung Biologics. Its niche focus on plasma fractionation R&D and ownership of proprietary plasma candidates are key differentiators against broader service providers.

More companies in Small Molecule Drugs →More companies in Germany →